Ticker Details
Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
IPO Date:	April 28, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.71B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.45 | 2.58%
Avg Daily Range (30 D):	$0.42 | 1.82%
Avg Daily Range (90 D):	$0.46 | 2.01%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.55M
Avg Daily Volume (90 D):	.9M

Trade Size
Avg Trade Size (Sh.):	98
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	66

Institutional Trades
Total Institutional Trades:	1,786
Avg Institutional Trade:	$1.75M
Avg Institutional Trade (30 D):	$1.82M
Avg Institutional Trade (90 D):	$2.02M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.41M
Avg Closing Trade (30 D):	$1.7M
Avg Closing Trade (90 D):	$1.96M
Avg Closing Volume:	99.82K

News

Feb 12, 2026 @ 11:00 AM Zymeworks To Report Fourth Quarter and Full Year 2... Source: Na

Jan 27, 2026 @ 11:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Na

Jan 7, 2026 @ 6:12 PM Jazz Pharmaceuticals' Drug Extends Survival Past T... Source: Vandana Singh

Jan 6, 2026 @ 6:34 PM Ziihera® (zanidatamab-hrii) Combinations Achiev... Source: Zymeworks Inc.

Nov 24, 2025 @ 11:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Zymeworks Inc.

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.26	$.03	$-.3
Diluted EPS	$-.26	$.03	$-.3
Revenue	$27.61M	$48.73M	$27.11M
Gross Profit
Net Income / Loss	$-19.6M	$2.32M	$-22.64M
Operating Income / Loss	$-22.11M	$-.67M	$-25.61M
Cost of Revenue
Net Cash Flow	$-33.42M	$22.05M	$10.1M
PE Ratio